Compare Incyte Corporation (INCY) vs Paycom Software Inc (PAYC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Paycom Software Inc — how do they compare? Incyte Corporation trades at $118.03 (market cap $23.11B), while Paycom Software Inc trades at $144.13 (market cap $6.98B). The key difference: Incyte Corporation is far larger — about 3.3× Paycom Software Inc's market cap, and Paycom Software Inc pays a 1% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | PAYC | |
|---|---|---|
Market Cap | $23.11B | $6.98B |
Sector | Health | Technology |
52-Week High | $118.52 | $238.80 |
52-Week Low | $67.38 | $113.59 |
Enterprise Value | $19.13B | $7.59B |
Dividend Yield | — | 1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
Paycom Software (PAYC) trades at $149.71, up 1.2% with a bullish technical signal supported by moving averages. The company shows strong profitability with 22.44% net income margin and 37.15% ROE, though recent Q3 2025 EPS slightly missed expectations. Recent developments include new asset management tool launches and board appointments, while analyst consensus sits at $151 price target with 47% buy ratings.
PAYC presents a balanced investment case with solid fundamentals and moderate valuation (P/E 17.12), though execution risks and competitive pressures in HCM software require monitoring. The stock's proximity to resistance at $152 suggests near-term consolidation potential, while earnings growth remains the key catalyst for further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Paycom Software Inc
Paycom is a fast-growing provider of payroll and human capital management, or HCM, software primarily targeting clients with 50-10,000 employees in the United States. Paycom was established in 1998 and services about 18,000 clients as of 2021, based on parent company grouping. Alongside its core payroll software, Paycom offers various HCM add-on modules, including time and attendance, talent management, and benefits administration.
Read more on PAYC →
